Business Context and Reporting Period
Company: Syndax Pharmaceuticals, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 8, 2016
Context: This filing reports corporate governance changes executed in connection with the closing of the Company's initial public offering (IPO) of common stock.
Financial Metrics
This filing does not contain financial performance data. There are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
- Corporate Charter: Filed an Amended and Restated Certificate of Incorporation with the Delaware Secretary of State effective immediately prior to the IPO closing.
- Bylaws: Adopted Amended and Restated Bylaws effective immediately prior to the IPO closing.
- Approvals: Both the Restated Certificate and Restated Bylaws were approved by the Board of Directors on September 28, 2015, and by stockholders on February 24, 2016.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, risk factors, or discussion of contingencies. The document is strictly procedural regarding the amendment of corporate governance documents.
Key Facts for Investor Verification
- Verify the terms of the Amended and Restated Certificate of Incorporation (Exhibit 3.1) and Bylaws (Exhibit 3.2) attached to the filing.
- Confirm the closing date and terms of the initial public offering referenced in the filing.
- Note that this 8-K does not provide financial statements; refer to the Company's S-1 registration statement or subsequent 10-K/10-Q filings for financial data.